Lennox-Gastaut Syndrome Research

Many new approaches to Lennox-Gastaut Syndrome (LGS) treatment have emerged in recent years. While there is still no cure for this condition, people affected by LGS now have more treatment options to choose from. Prognosis for LGS varies from one patient to another, though complete recovery from seizures and other developmental complications is very rare.

A lot more research is needed in this area to design better therapies for the various types of LGS. Advances in detection and recording of seizures are the need of the hour.  Treatments and services that aim at improving safety and quality of life for children affected by LGS is another area of focus for researchers.

Organizations Supporting LGS

Several non-profit support and advocacy groups across the US and other countries help in bringing together patients, caregivers, researchers, and healthcare professionals. These organizations work towards raising awareness about the condition and providing support to the patients and caregivers.

They are also the driving force behind research focusing on better treatment methods and potential cures for the condition. Many of these groups comprise doctors and medical experts.

Some of the key organizations supporting this condition include:

  • The Epilepsy Foundation
  • International Foundation for CDKL5 Research
  • LGS Foundation
  • Intractable Childhood Epilepsy Alliance (ICE)
  • American Epilepsy Society
  • CURE: Citizens United for Research in Epilepsy
  • Genetic and Rare Diseases (GARD) Information Center
  • National Institute of Health (NIH)/National Institute of Neurological Disorders and Stroke (NINDS)

National Institute of Neurological Disorders and Stroke

NINDS conducts, as well as supports, a wide range of basic and clinical research programs on epilepsy including LGS. The key objectives of these research studies are identifying causes of LGS and other related disorders, enhancing diagnostic methods, and developing new therapies and medications.

LGS Foundation

The LGS Foundation focuses on improving the quality of life of individuals with LGS. This is achieved through education and research programs. Years of research by physicians and scientists have contributed to the modern understanding of LGS and improved treatment options and quality of life of people affected by the condition. However, there is still a huge amount of research to be done. LGS is often considered a tough condition to study due to its heterogeneity and the LGS Foundation plays a key role in advancing research in this area.

Research on the Effects of Medical Marijuana on LGS

Several scientific studies on the effect of medical marijuana on LGS have concluded that cannabidiol, a cannabinoid present in cannabis, is a promising treatment option that is capable of reducing or eliminating seizures. One preclinical trial conducted in 2013 showed that cannabis administration caused significant anticonvulsant effects in rats and mice.

Studies show that cannabidiol has peculiar effects on the endocannabinoid system of the body, which helps in the reduction or elimination of seizures. It activates the cannabinoid receptor 1 (CB1), which inhibits the release of neurotransmitter thus causing an overall reduction in excitability of neurons.

Although placebo-controlled studies on effects of cannabis on LGS are currently unavailable, basic research shows that cannabis is very effective in treating epilepsy related conditions such as LGS in children.

In a questionnaire-based study, 84% of participants reported a reduction in frequency of seizures post treatment with cannabis. Out of the 84%, approximately 11% of the participants reported complete freedom from seizures and 42% reported over 80% decrease in seizure frequency.


Further Reading

Last Updated: May 26, 2023

Susha Cheriyedath

Written by

Susha Cheriyedath

Susha is a scientific communication professional holding a Master's degree in Biochemistry, with expertise in Microbiology, Physiology, Biotechnology, and Nutrition. After a two-year tenure as a lecturer from 2000 to 2002, where she mentored undergraduates studying Biochemistry, she transitioned into editorial roles within scientific publishing. She has accumulated nearly two decades of experience in medical communication, assuming diverse roles in research, writing, editing, and editorial management.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Cheriyedath, Susha. (2023, May 26). Lennox-Gastaut Syndrome Research. News-Medical. Retrieved on July 13, 2024 from https://www.news-medical.net/health/Lennox-Gastaut-Syndrome-Research.aspx.

  • MLA

    Cheriyedath, Susha. "Lennox-Gastaut Syndrome Research". News-Medical. 13 July 2024. <https://www.news-medical.net/health/Lennox-Gastaut-Syndrome-Research.aspx>.

  • Chicago

    Cheriyedath, Susha. "Lennox-Gastaut Syndrome Research". News-Medical. https://www.news-medical.net/health/Lennox-Gastaut-Syndrome-Research.aspx. (accessed July 13, 2024).

  • Harvard

    Cheriyedath, Susha. 2023. Lennox-Gastaut Syndrome Research. News-Medical, viewed 13 July 2024, https://www.news-medical.net/health/Lennox-Gastaut-Syndrome-Research.aspx.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.